Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991922 · ClinicalTrials.gov registry record
BostonGene-Integrated Genomic Registry (BIGR)
A clinical trial of Malignancy, sponsored by BostonGene.
- Recruiting
- Registry status
- 100,000
- Enrollment target
- 1
- Study location
NCT04991922: Recruiting study of Malignancy, sponsored by BostonGene.
NCT04991922 is a study of Malignancy that is actively recruiting participants, run by BostonGene. The registered enrollment target is 100,000 participants, above the 87-participant average among 8 other Malignancy trials with a reported enrollment target (114843% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04991922, a study of Malignancy, is actively recruiting participants, sponsored by BostonGene.
- RECRUITING
- Registry status
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Primary Outcome
associations between genomic findings and outcomes of cancer patients who have undergone comprehensive sequencing.
Conditions Studied
Study Locations (1)
Massachusetts
- BostonGene - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2036-07-01 |
What NCT04991922 shows while recruiting
NCT04991922 is an observational study that tracks outcomes without assigning an intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 87-participant average among 8 other Malignancy trials with a reported enrollment target (114843% higher).
The record links to 1 condition, with Malignancy appearing as the primary indexed condition, and to 0 interventions.
NCT04991922 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04991922 about?
NCT04991922 is a clinical study titled "BostonGene-Integrated Genomic Registry (BIGR)". The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
What is the current status of trial NCT04991922?
This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2021-07-01. Estimated completion is 2036-07-01.
What conditions does trial NCT04991922 study?
This clinical trial studies the following conditions: Malignancy.
Who is sponsoring clinical trial NCT04991922?
This trial is sponsored by BostonGene, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04991922 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04991922's enrollment target sits among peer trials
100,000 1st of 8 higher than 8 of 8 other Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
RECRUITING · NA
-
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
RECRUITING · Phase 1
-
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
RECRUITING
-
Immuno-Oncology Database and Bioregistry
ACTIVE NOT RECRUITING
-
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI